Security key
558868105
MADRIGAL PHARMACEUTICALS, INC. - Common Stock (MDGL)
CUSIP: 558868105
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 771,768
- Total 13F value
- $413,255,341
- Share change
- +101,089
- Put/Call ratio
- 94%
- SEC-reported price per share
- $536.95
- Number of holders
- 104
- Value change
- +$55,008,258
- Number of buys
- 55
- Number of sells
- 34
- Shares outstanding
- 23,203,174
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
104
Top holders
10
MDGL full security history
Ownership snapshot
Full 13F holder table
MADRIGAL PHARMACEUTICALS, INC. SEC filings
MADRIGAL PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of MDGL - MADRIGAL PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 8.8%
13D/G row: Janus Henderson Group Ltd.
Showing 1-6 of 15 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 8.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
8.8%
Paul A. Friedman
7.8%
Rebecca Taub
7.8%
PAULSON & CO. INC.
6.1%
BlackRock, Inc.
4.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
13F
JANUS HENDERSON GROUP PLC · Company
|
8.8%
|
$1,077,715,260
2,018,647 shares
|
+$231,599,280 | 31 Mar 2026 |
| Paul A. Friedman |
13D/G
3/4/5
Paul A Friedman, M.D. · Director
|
7.8%
|
$982,730,986
1,814,831 shares
|
$0 | 10 Dec 2025 |
| Rebecca Taub |
13D/G
3/4/5
Rebecca Taub, M.D. · Director
|
7.8%
|
$982,730,986
1,814,831 shares
|
$0 | 10 Dec 2025 |
| PAULSON & CO. INC. |
13D/G
13F
Company
|
6.1%
|
$743,261,329
1,392,188 shares
|
-$168,350,516 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
4.6%
from 13D/G
|
$816,594,622
1,559,965 shares
|
— | 31 Mar 2026 |
| Kenneth Bate |
3/4/5
Director
|
0.01%
|
$1,289,808
2,627 shares
|
-$11,679,363 | 05 Nov 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
104
Shares
771,768
Rows available
104
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
374
Q2 2026 holders
104
Holder diff
-270
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|